Ephicacy Consulting Group, Inc. has recently made an exciting announcement regarding its acquisition of Advance Research Associates (ARA), a company specializing in data management and biostatistical consulting services for clinical trials. This strategic move aims to enhance Ephicacy’s capabilities in biostatistics and data management, further bolstering the range of solutions it offers to pharmaceutical, biotechnology, and medical device companies.
With its foundation in 2005, Ephicacy has become a leading biometrics Contract Research Organization (CRO), providing clinical analytics services by leveraging its talented workforce from around the world. The company offers flexible service delivery options, including Functional Service Provider (FSP) and project-based solutions to cater to its diverse global client base.
As part of the acquisition, Peter Shabe, the Founder and CEO of ARA, will join Ephicacy as the Global Head of Biostatistics Consulting. Alongside him, a team of skilled statisticians and data management experts from ARA will also become a part of Ephicacy’s growing team.
Ganesh Gopal, the CEO of Ephicacy, expressed excitement about the acquisition, highlighting the value of the expertise and experience that ARA brings to the table. He emphasized the need for reliable partners who can navigate the complexities of data in clinical trials, and with this acquisition, Ephicacy aims to deepen its biostatistics and data management solutions to drive impactful outcomes for clients and patients.
Since its establishment in 1996, ARA has been providing customized data management and biostatistical consulting services to clients in the pharmaceutical, biotech, medical device, and diagnostic industries. Joining forces with Ephicacy is seen as a natural evolution of ARA’s mission, and both companies share similar goals and core values.
Ephicacy, headquartered in Iselin, NJ, has a strong presence in North America and India, and has positioned itself as a prominent player in the clinical analytics space. The company offers a range of services including statistical programming, biostatistics, data management, and real-world evidence analytics to pharmaceutical and biotechnology companies, helping them reduce their time to market in a cost-effective manner.
For more information about Ephicacy and its services, visit www.ephicacy.com.
Source: Business Wire
Ephicacy Consulting Group’s recent acquisition of Advance Research Associates (ARA) is aimed at strengthening the company’s biostatistics and data management capabilities. This strategic move is expected to provide Ephicacy with a broader range of solutions for its clients in the pharmaceutical, biotechnology, and medical device industries.
With its foundation in 2005, Ephicacy has become a leading biometrics Contract Research Organization (CRO), offering clinical analytics services to a global client base. The company differentiates itself by providing flexible service delivery options such as Functional Service Provider (FSP) and project-based solutions.
The acquisition of ARA brings Peter Shabe, the Founder and CEO of ARA, to Ephicacy as the Global Head of Biostatistics Consulting. Shabe’s expertise, along with a team of skilled statisticians and data management experts from ARA, will further strengthen Ephicacy’s capabilities in these areas.
Ganesh Gopal, the CEO of Ephicacy, emphasizes the importance of reliable partners who can navigate the complexities of data in clinical trials. With this acquisition, Ephicacy aims to deepen its biostatistics and data management solutions to drive impactful outcomes for clients and patients.
Advance Research Associates, established in 1996, has been providing customized data management and biostatistical consulting services to clients in the pharmaceutical, biotech, medical device, and diagnostic industries. The joining of forces with Ephicacy is seen as a natural evolution of ARA’s mission, as both companies share similar goals and core values.
Ephicacy, headquartered in Iselin, NJ, has a strong presence in North America and India. The company is known for its expertise in statistical programming, biostatistics, data management, and real-world evidence analytics. These services help pharmaceutical and biotechnology companies reduce time to market in a cost-effective manner.
Market Trends and Forecasts:
– The demand for biostatistics and data management services is expected to witness steady growth in the coming years. As the pharmaceutical and biotechnology industries continue to expand and invest in clinical trials, the need for reliable and efficient data management solutions becomes crucial.
– The increasing adoption of advanced analytics and artificial intelligence in clinical trials is expected to drive the market for biostatistics and data management services. These technologies enable better data analysis, decision-making, and patient stratification, leading to improved drug development processes.
– The global biostatistics services market is projected to reach a value of $3.9 billion by 2027, growing at a CAGR of 12.4% from 2020 to 2027. Factors such as the rising number of clinical trials, increasing outsourcing of biostatistics services, and the importance of data-driven decisions in drug development contribute to this growth.
Key Challenges and Controversies:
– One key challenge in biostatistics and data management is ensuring data quality and integrity. Accurate and reliable data is crucial for making robust conclusions and regulatory compliance. The proper implementation of data standards and data cleaning processes is necessary to address this challenge.
– Another challenge is managing the large volumes of data generated in clinical trials. As clinical trials become more complex and incorporate various data sources, including electronic health records and wearable devices, effective data management becomes critical. The challenge lies in leveraging technologies and tools to handle and integrate these diverse data sources efficiently.
– There may also be controversies surrounding data privacy and security. With the increasing focus on data sharing and collaboration, ensuring the protection of sensitive patient information and maintaining regulatory compliance becomes a priority.
Advantages of the Acquisition:
– Strengthening biostatistics and data management capabilities: The acquisition allows Ephicacy to enhance its expertise in these areas, enabling it to provide more comprehensive solutions to its clients.
– Expansion of talent pool: With the addition of ARA’s team of skilled statisticians and data management experts, Ephicacy can leverage a wider range of skills and experience to deliver high-quality services.
– Broader client base: The acquisition may open doors to new clients and industries, as both companies have served clients in different sectors. This diversification can contribute to sustained growth and business opportunities.
Disadvantages of the Acquisition:
– Integration challenges: Merging two companies and aligning their processes and systems can be complex and time-consuming. The success of the acquisition relies on effective integration strategies and seamless collaboration between teams.
– Cultural differences: There may be challenges in aligning the cultures and work styles of the two companies. Building a cohesive and collaborative culture is crucial for smooth operations and client satisfaction.
For more information about Ephicacy and its services, visit www.ephicacy.com.
Source: Business Wire